AUG 22, 2018 09:43 PM PDT

New Clinical Assay Useful For Urothelial Cancer

WRITTEN BY: Nouran Amin

U.S. Food and Drug Administration (FDA) has now approved a pharmDx assay called ‘Dako PD-L1 IHC 22C3’ by Agilent Technologies Inc. for use in urothelial carcinoma. The assay is the only approved companion diagnostic to help identify patients with urothelial carcinoma for treatment with KEYTRUDA, which is a monoclonal anti-PD1 therapy manufactured by the pharmaceutical company known Merck for the first-line treatment option of cancer.

Specifically, KEYTRUDA is approved for cancer patients experiencing locally advanced or metastatic urothelial carcinoma and who are not eligible for cisplatin-containing chemotherapy. Additionally, their tumors must express PD-L1 [Combined Positive Score (CPS) ≥ 10] as determined through an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy.

The pharmDx assay referred to as ‘PD-L1 IHC 22C3’ follows previous FDA-approved assay for non-small cell lung cancer (NSCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, and cervical cancer. "Anti-PD-1 therapies are a promising treatment class for many cancer types, and early PD-L1 testing can provide critical information to physicians managing urothelial carcinoma patients," explains Sam Raha, the president of Agilent's Diagnostics and Genomics Group. "By expanding the use of PD-L1 IHC 22C3 pharmDx, Agilent strives to address the unmet need for treatment options in patients who are ineligible for cisplatin-containing chemotherapy. Through these efforts, we maintain our commitment to bringing companion diagnostics to the market in support of groundbreaking immuno-oncology therapeutics."

The 5th most common cancer in the United States, urothelial carcinoma holds an estimated incidence of 81,000 new diagnoses in just 2018. For 30 years, cancer-related morality has not approved for patients with advanced/metastatic urothelial carcinoma with a five-year survival rate of approximately 15%. Additionally, the age along with disease-associated comorbidities affect patient eligibility for standard treatments such as cisplatin-containing chemotherapy. Patients that cannot be administered cisplatin-containing chemotherapy, will have an unmet need for effective therapy.

Source: Agilent

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 19, 2018
Clinical & Molecular DX
APR 19, 2018
Could a blood test detect lung cancer?
Lung nodules are more common than most people think, and they’re benign more often than they are malignant. From the Medical University of South Caro...
APR 30, 2018
Clinical & Molecular DX
APR 30, 2018
Reducing Dependency on Antibiotics in Hospitals
How can small community and rural hospitals create antibiotic stewardship programs to reduce the danger of antibiotic resistance? Scientists from the Inter...
MAY 23, 2018
Technology
MAY 23, 2018
Building Block Medical Test Is Reusable
MIT's Little Devices Lab has created a more affordable solution called Ampli blocks that consists of modular diagnostic kits, which can be re-oriented and reused....
JUN 08, 2018
Clinical & Molecular DX
JUN 08, 2018
Early Detection of Tooth Decay from Bacterial Invasion
We all get cavities, but have we ever thought much about the biology of the process? From the Akson Russian Science Communication Association, scientists i...
JUN 30, 2018
Immunology
JUN 30, 2018
CD4 T Cells Responsible for Inflammatory Bowel Disease
A specific subset of immune cells could be targeted to better treat inflammatory bowel disease (IBD). A new University of Alabama at Birmingham study point...
SEP 01, 2018
Clinical & Molecular DX
SEP 01, 2018
Spit Test for Zika Evolves From HIV Detection
Researchers are developing a test for Zika that uses saliva to identify diagnostic markers of the virus much more quickly than current commercial tests can...
Loading Comments...